WINTON GROUP Ltd Takes $362,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

WINTON GROUP Ltd purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,924 shares of the biopharmaceutical company’s stock, valued at approximately $362,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Southland Equity Partners LLC grew its position in shares of Gilead Sciences by 3.6% during the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 110 shares during the period. Berkshire Bank grew its holdings in Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 111 shares during the period. CFO4Life Group LLC increased its position in shares of Gilead Sciences by 2.7% in the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 112 shares in the last quarter. GHP Investment Advisors Inc. raised its stake in shares of Gilead Sciences by 1.1% during the 4th quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock worth $1,049,000 after buying an additional 122 shares during the period. Finally, J.W. Cole Advisors Inc. raised its stake in shares of Gilead Sciences by 1.0% during the 4th quarter. J.W. Cole Advisors Inc. now owns 13,597 shares of the biopharmaceutical company’s stock worth $1,256,000 after buying an additional 135 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.6 %

Shares of GILD stock opened at $111.79 on Monday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The firm has a market cap of $139.22 billion, a PE ratio of 302.14, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a 50-day moving average of $105.48 and a two-hundred day moving average of $95.00. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.83%. The ex-dividend date was Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is currently 854.05%.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the sale, the chief financial officer now owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. This represents a 9.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 302,785 shares of company stock valued at $30,503,250. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on GILD. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Royal Bank of Canada raised their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 11th. Wells Fargo & Company increased their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Finally, Bank of America lifted their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $105.12.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.